Aegerion Pharmaceuticals, Inc. Cashflow Statement

Ask AI

Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated Statements of Cash Flows

In millions of USD, except per-share amounts

	FY2015 12 months to Dec 31, 2015	FY2014 12 months to Dec 31, 2014	FY2013 12 months to Dec 31, 2013	FY2012 12 months to Dec 31, 2012	FY2011 12 months to Dec 31, 2011
Operating activities
Net loss
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:
Depreciation
Amortization of intangible assets
Amortization of premium on marketable securities
Stock-based compensation
Noncash interest expense
Noncash rent expense
Noncash restructuring costs

Deferred rent expense
Noncash interest expense
Provision for inventory excess and obsolescence
Other non-cash losses
Excess tax benefit from stock-based compensation
Noncash restructuring costs
Impairment loss on investments in securities and other non-cash (gains)/losses
Loss on extinguishment of debt
Excess tax expense (benefit) from stock-based compensation
Unrealized foreign exchange loss
Loss on disposal of property and equipment
Deferred income taxes
Deferred rent
Other liabilities
Net cash used in operating activities
Changes in assets and liabilities, excluding the effect of acquisition:
Restricted cash
Accounts receivable
Inventories
Prepaid expenses and other assets
Other long-term assets
Accounts payable
Other accrued liabilities
Accrued liabilities
Accrued and other liabilities

Net cash provided by (used in) operating activities

Investing activities
Purchases of property and equipment
Payment for acquisition of MYALEPT
Purchases of marketable securities
Maturities of marketable securities
Sales and redemptions of marketable securities
Net cash (used in) provided by investing activities
Financing activities
Proceeds from long-term debt, net
Increase in restricted cash to collateralize long-term debt in default
Change in restricted cash
Proceeds from issuances of convertible notes
Proceeds from issuances of warrants
Purchase of convertible bond hedges
Principal repayment of long-term debt
Repurchase of common stock
Payments for withholding taxes on restricted stock units
Proceeds from exercises of stock options
Payment of financing fees
Excess tax expense (benefit) from stock-based compensation
Proceeds from issuances of common stock, net of offering expenses
Deferred financing fees
Net cash provided by financing activities
Debt extinguishment fee
Proceeds from issuances of notes payable
Payment of notes payable
Net cash (used in) provided by financing activities
Exchange rate effect on cash
Net (decrease) increase in cash and cash equivalents
Cash and cash equivalents, beginning of period
Cash and cash equivalents, end of period

Supplemental disclosures of cash flow information
Cash paid for interest
Cash paid for taxes
Deferred charge due on maturity of Hercules term loan
Warrant issued with notes payable

Non-cash investing activities
Purchases of property and equipment included in accounts payable

Comments